Postpartum psychosis (PPP) is a rare but serious condition, occurring in 1 to 2 per 1000 women in the weeks after delivery and associated with extreme delirium-like behavior, delusions, hallucinations, and an increased risk of [...]
Our group will be traveling to Albany, New York this Friday, October 12th, to take part in the New York State Conference on Maternal Depression sponsored by Project TEACH. We will be joining our colleagues [...]
In our clinic, we are seeing more and more women of reproductive age using marijuana in various forms. According to research published in the Journal of the American Medical Association, there has been a significant [...]
Two new studies explore the efficacy of non-pharmacologic treatments for depression during pregnancy. The first uses internet-derived cognitive behavioral therapy (Loughnan et al, 2018) in a group of pregnant women with anxiety and/or depression. The [...]
The American College of Obstetrics and Gynecology now recommends that women be screened for depression during pregnancy in addition to screening during the postpartum period. Because depressive symptoms during pregnancy have been associated with worse [...]
This week’s offering includes an article published in Pediatrics indicating that cannabis metabolites are found in the breast milk up to 6 days after the last use. A small prospective study from Wisner and colleagues [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD). SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors. We saw the preliminary [...]
August 23, 2018 from ObGynNews The management of bipolar disorder during pregnancy is a critical clinical situation demanding great attention to issues such as reproductive safety of psychiatric medications used by women with bipolar disorder [...]
Data on the most recent randomized controlled trial of brexanolone, a novel treatment for postpartum depression, were released. (We will review those in greater detail next week.) Guidelines for the treatment of perimenopausal depression were [...]
Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule. Freeman MP, Farchione T, Yao L, Sahin L, Taylor L, Huybrechts KF, Nonacs R, Sosinsky AZ, [...]